XML 99 R69.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements and Investments - Additional Information (Detail)
SFr in Millions
12 Months Ended
Oct. 01, 2020
USD ($)
Dec. 31, 2021
USD ($)
Apr. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Oct. 10, 2021
USD ($)
Oct. 10, 2021
CHF (SFr)
Oct. 01, 2020
CHF (SFr)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Convertible loans $ 5,000,000.0            
Maximum [Member] | Spinal Kinetics [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Future milestone payments     $ 60,000,000.0        
US Food And Drug Administration [Member] | Spinal Kinetics [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Future milestone payments     15,000,000.0        
Revenue Milestone [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Future milestone payments   $ 15,000,000.0          
Revenue Milestone [Member] | Spinal Kinetics [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Future milestone payments     $ 45,000,000.0        
Neo Medical [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Convertible loans         $ 700,000 SFr 0.6 SFr 4.6
Convertible loans interest rate 8.00%           8.00%
Maturity date Oct. 01, 2024            
Convertible loan credit losses       $ 0      
Preferred Stock [Member] | Neo Medical [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Amount of Preferred stock consideration $ 5,000,000.0            
Unrealized gain (loss) on equity investments   $ 336,000